Join
Live feed
·
PRReleasevia Quantisnow
Vaxart Inc logo

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

ByQuantisnow·Wall Street's wire, on your screen.
VXRT· Vaxart Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VXRT (Vaxart Inc) and more on Quantisnow.